Skip Navigation

Adalvo expands its Dermatology Portfolio with Dimetindene Gel 0.1%(1mg/g)

26 July 2023

Adalvo is delighted to highlight the expansion of its portfolio with the well-established Dimetindene Gel 0.1% (1mg/g).

This product has been developed based on the reference brand Fenistil Gel, and is intended for use in rashes, itching, non-inflammatory skin diseases, burns, insect bites, allergic dermatitis and eczema. Dimetindene Gel 0.1%(1mg/g) sold at $65M globally in 2022, according to IQVIA.

The successful development of this product further highlights Adalvo's ability to offer difficult-to-make, high-value products to their partners.

As a company committed to our dermatology portfolio, Adalvo offers an array of dossiers and aims to assist our partners in overcoming any challenges that may arise with these mature products.

Our dermatology products include:

  • Adapalene Gel
  • Adapalene + Benzoyl Peroxide Gel
  • Tacrolimus Ointment
  • Dimetindene Gel

Partner up now! 

At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward. – Central & Eastern Europe, Russia & CIS North Europe, APAC, MENA & Israel – Brazil - LATAM (exc. Brazil) & South Europe – Europe – UK/Ireland, North America & South Africa - LATAM (exc. Brazil) - Head of Global BD&L

Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.